CNS Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Net cash NAV: $20.0M cash & equivalents (6/30/26) minus $3.74M total liabilities = $16.26M net cash, divided by 10,604,928 fully-diluted shares (incl. pre-funded warrants from the May 2026 raise, which are economically equivalent to common shares).

Reasoning: CNS Pharmaceuticals is pivoting away from its legacy Berubicin program toward out-licensing/acquiring new assets with no committed near-term revenue or late-stage pipeline value that can be reliably rNPV'd, so a cash-flow DCF would be an ungrounded guess; net cash is the most defensible, fully data-backed floor value.